Psilocybin-Assisted Therapy Shows Promise for Mental Health in Cancer Patients and Alcohol Use Disorder
Psilocybin-assisted psychotherapy significantly reduced anxiety, depression, and other psychological distress in cancer patients, with benefits lasting up to six months.
Switching from Entecavir to Tenofovir Alafenamide Shows Similar Efficacy in Chronic Hepatitis B
A recent study found that switching from entecavir (ETV) to tenofovir alafenamide (TAF) in chronic hepatitis B patients showed similar effects on serum HBsAg levels over 240 weeks.
Wockhardt's Zaynich Demonstrates Superior Efficacy in Phase III cUTI Trial
Wockhardt's Zaynich (zidebactam/cefepime) achieved superiority over meropenem in a Phase III trial for complicated urinary tract infections (cUTI).
Unity Biotechnology's UBX1325 Shows Promise for Diabetic Macular Edema Treatment
Unity Biotechnology's UBX1325, a senolytic therapy, targets diabetic macular edema (DME) by addressing treatment burdens and suboptimal responses.
CRISPR Repairs Limb-Girdle Muscular Dystrophy 2B Mutation and Phenotypes in Patient-Derived Cells
Researchers have developed a CRISPR-based gene correction strategy to restore dysferlin function in cells from patients with limb-girdle muscular dystrophy 2B (LGMD2B), a rare genetic disorder. This approach successfully corrected a common frameshift mutation in the DYSF gene, leading to the restoration of full-length, functional dysferlin protein in patient-derived cells and a newly developed mouse model.
Duvakitug Shows Promise in Phase 2 Ulcerative Colitis Trial with 50% Symptom Resolution Rate
A Phase 2 trial of duvakitug, jointly developed by Teva and Sanofi, has demonstrated significant efficacy in treating ulcerative colitis. The experimental antibody drug achieved symptom resolution in approximately 50% of patients receiving high doses after 14 weeks, compared to 20% in the placebo group.
Mepolizumab Demonstrates Sustained Efficacy in Chronic Rhinosinusitis with Nasal Polyps: Real-World Evidence
Mepolizumab significantly reduced SNOT-22 and NPS scores in CRSwNP patients at 6 and 12 months, indicating improved quality of life and reduced polyp size.
IDEAYA's Darovasertib and Crizotinib Combination Advances in Uveal Melanoma Trial
IDEAYA Biosciences' combination therapy of darovasertib and crizotinib receives IDMC recommendation to advance to Part 2b of Phase 2/3 trial.
Duvakitug Shows Promise in Phase 2b Trial for Ulcerative Colitis and Crohn's Disease
Teva and Sanofi's duvakitug met primary endpoints in a Phase 2b trial for ulcerative colitis (UC) and Crohn's disease (CD).
Gecacitinib Demonstrates Superior Spleen Volume Reduction in Myelofibrosis Patients Compared to Hydroxyurea
Gecacitinib significantly improved spleen volume reduction (SVR35) at 24 weeks compared to hydroxyurea (HU) in patients with intermediate-2 or high-risk myelofibrosis, with a 64.8% vs 26.5% response rate.
Verastem Oncology's RAMP 203 Trial Shows Encouraging Initial Data for Triplet Combination in Advanced KRAS G12C Mutant NSCLC
Verastem Oncology's RAMP 203 trial evaluates avutometinib and sotorasib with or without defactinib in KRAS G12C mutant non-small cell lung cancer (NSCLC).
Wegovy Reduces Cardiovascular Risk by 20% in Obese Patients with Heart Disease History
Novo Nordisk's Wegovy demonstrated a 20% reduction in the risk of stroke, heart attack, and other cardiovascular events in overweight individuals with prior heart disease.
Coherus' Casdozokitug Shows Promising Results in Liver Cancer Phase 2 Trial
Coherus BioSciences presented final Phase 2 data for casdozokitug combined with atezolizumab and bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma.
FDA Grants Priority Review to GSK's Jemperli for Advanced Endometrial Cancer
The FDA has granted Priority Review to GSK's Jemperli (dostarlimab) in combination with chemotherapy for advanced or recurrent endometrial cancer.
Global Real-World Study Launches to Evaluate Faricimab's Long-Term Impact in Retinal Diseases
A new two-year observational study, FaReal, has been initiated to assess the real-world effectiveness and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The study aims to provide comprehensive insights into treatment patterns and health economic implications of faricimab compared to previous anti-VEGF therapies.
Biocon and Zentiva Secure EU Approval for Liraglutide, a Generic Version of Victoza
Biocon and Zentiva have received EU approval for their generic Liraglutide formulation via a decentralized procedure, targeting Type-2 Diabetes and weight management.
AusperBio Secures $73 Million to Advance Chronic Hepatitis B Therapy
AusperBio has successfully completed a $73 million Series B financing round to advance its lead therapy, AHB-137, for a functional cure for chronic hepatitis B.
Cereno Scientific Expands Access to CS1 for Pulmonary Arterial Hypertension
Cereno Scientific has enrolled nine additional patients in its Expanded Access Program (EAP) for CS1, a drug candidate for pulmonary arterial hypertension (PAH).
FDA Approves Expansion of Patient Enrolment in Sequana Medical's POSEIDON Study for Alfapump Treatment
Sequana Medical has received FDA approval to expand patient enrolment in its North American pivotal study, POSEIDON, for the alfapump treatment of recurrent or refractory ascites due to liver cirrhosis. The expansion aims to compensate for higher attrition rates, with the goal of implanting the alfapump in 50 patients. The study is on track for primary endpoint read-out in Q4 2022 and FDA regulatory submission by mid-2023.
Yale Surgeon-Scientist Secures FDA Orphan Drug Designation for Pembrolizumab in Rare Respiratory Disease
Yale School of Medicine surgeon-scientist Sara Pai, MD, PhD, has achieved FDA orphan drug designation for pembrolizumab to treat recurrent respiratory papillomatosis (RRP), a rare condition caused by HPV. This designation, based on a clinical trial showing significant benefits for RRP patients, highlights the innovative role of surgeon-scientists in advancing treatments.